The last few months have been very eventful for LIDDS; the last patient has been enrolled in their localized treatment of prostate cancer study and they are evaluating a possible listing on Nasdaq Stockholm’s Main Market. The CEO of LIDDS, Monica Wallter, gives us an update. What’s next for LIDDS and what results can we … Continue reading Mini-interview: Monica Wallter, CEO of LIDDS